Fermenta BiotechQ4 FY22

Fermenta Biotech Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹465.5P/E: 29.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue.
  • New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth.
  • The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth.
  • The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.
  • Animal feed volumes and prices have been volatile and suppressed; a recovery could lead to improved margins and higher revenues, but this remains uncertain.
  • The management refrains from giving specific volume guidance due to market volatility but remains confident in achieving an average EBITDA margin of around 20% over 4-5 years, reflecting steady operational growth.

See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company is being cautious about over-leveraging and does not plan to significantly increase debt for upcoming CAPEX requirements, particularly for the Saykha project.
  • For certain new products like pre-mixes, the company has already taken additional debt, increasing it by about Rs. 25 to 30 crores for the Kullu project.
  • No anticipated CAPEX-related debt is expected for new products like Vitamin K1 and vegan D3 as they will utilize existing multi-purpose plants.
  • The company is monetizing land assets (e.g., Thane, Pune) to fund investments, aiming to avoid increasing debt levels.
  • No specific mention of equity fundraising was indicated in the transcript.

See what Fermenta Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions (Page 13).
  • Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22 (Page 8 and 13).
  • Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products (Page 10 and 14).
  • Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets (Page 12, 13).
  • Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure (Page 12).
  • No anticipated CAPEX for new products like K1 and vegan D3 initially, leveraging existing Dahej plant capacity (Page 13).
  • Debt increased by Rs. 25-30 crores for Kullu pre-mix plant; no significant additional debt planned currently (Page 12).

Track Fermenta Biotech — get its next earnings analysis in your feed

How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisFermenta Biotech
Rev 3Mar 3

How does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →